June Sherie Almenoff
CIK 1492647 · COO and Chief Medical Officer · last filed 2026-01-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$144.3K
Companies
7
Total Filings
46
Lifetime Open-Market Net
-$13.02M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TENX | Director | 3,986 | $15.80 | $63.0K | $29.9K | 7 | 2026-01-13 |
| AVTX | Director | 4,167 | $19.52 | $81.3K | $12.7K | 14 | 2025-06-18 |
| ATNM | Director | — | $0.87 | — | $0 | 2 | 2025-04-02 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted | Director | 878 | $0.75 | $657 | $25.0K | 6 | 2021-12-17 |
| 9 METERS BIOPHARMA, INC. (INNT) Delisted | COO and Chief Medical Officer | 1,400 | — | — | $6.9K | 1 | 2018-08-28 |
| NeuBase Therapeutics, Inc. (OHRP) Delisted | Director | 16,900 | — | — | $58.3K | 5 | 2017-10-18 |
| Furiex Pharmaceuticals, Inc. (FURX) Delisted | President | 139,713 | — | — | -$13.15M | 10 | 2014-02-06 |
Recent Filings · Page 3 of 5
46 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-01-04 | AVTX | Grant (A) | — | $0 | EDGAR |
| 2021-12-17 | BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted | Grant (A) | +2,000 | $0 | EDGAR |
| 2021-12-10 | BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted | Grant (A) | +2,000 | $0 | EDGAR |
| 2021-11-12 | AVTX | Grant (A) | — | $0 | EDGAR |
| 2021-06-15 | TENX | Grant (A) | — | $0 | EDGAR |
| 2020-02-14 | BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted | Grant (A) | +2,000 | $0 | EDGAR |
| 2019-01-08 | BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted | Buy (P) | +1,475 | $5.0K | EDGAR |
| 2018-08-28 | 9 METERS BIOPHARMA, INC. (INNT) Delisted | Buy (P) | +1,400 | $6.9K | EDGAR |
| 2018-03-20 | BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted | Buy (P) | +5,700 | $19.9K | EDGAR |
| 2018-03-16 | BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted | Grant (A) | +5,700 | $19.9K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.